Evidence map›Paper›PMID 34782394›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022

Vaccination History and Risk of Lymphoma and Its Major Subtypes.

Geffen Kleinstern, Melissa C Larson, Stephen M Ansell, Carrie A Thompson, Grzegorz S Nowakowski, Timothy G Call, Dennis P Robinson, Matthew J Maurer, Raphael Mwangi, Andrew L Feldman and 5 more

Open access · bronzeAbstract readComment
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. No Association of Prior Administration of Selected Vaccines with Lymphoma Prognosis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026
    Article
  3. Article
  4. Evaluation of Etiologic Heterogeneity for Risk of Diffuse Large B-Cell Lymphoma Subtype Defined by the Cell of Origin.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Geffen KleinsternSchool of Public Health, University of Haifa, Haifa, Israel.
Melissa C LarsonDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Stephen M AnsellDivision of Hematology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0003-1244-6758
Carrie A ThompsonDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
Grzegorz S NowakowskiDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
Timothy G CallDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
Dennis P RobinsonDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Matthew J MaurerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-1867-0526
Raphael MwangiDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.
Andrew L FeldmanDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0001-5009-4808
Neil E KayDivision of Hematology, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-5951-5055
Anne J NovakDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
Thomas M HabermannDivision of Hematology, Mayo Clinic, Rochester, Minnesota.
Susan L SlagerDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.ORCID 0000-0002-5173-4712
James R CerhanDepartment of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota. cerhan.james@mayo.edu.ORCID 0000-0002-7482-178X
Mayo Clinic · USMayo Clinic in Florida · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI LENTZ, STEVEN R · 2002 to 2021
$45.7M
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study (Supplement)U01CA195568 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R, FLOWERS, CHRISTOPHER R · 2015 to 2025
$22.1M
Molecular Epidemiology of NHL and CLLR01CA092153 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R · 2003 to 2012
$6.7M
NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA097274NCI NIH HHS R01 CA092153NCI NIH HHS U01 CA195568
6 · The paper itself

Abstract

backgroundVaccinations have been hypothesized to play a role in lymphoma etiology, but there are few studies, mixed results, and limited data on lymphoma subtypes. Herein, we investigate the association of vaccinations with risk of major lymphoma subtypes.

methodsWe studied 2,461 lymphoma cases and 2,253 controls enrolled from 2002 to 2014. Participants self-reported history of vaccinations against hepatitis A, hepatitis B, yellow fever, and influenza. Polytomous logistic regression was used to estimate OR and 95% confidence intervals (CI), adjusting for potential confounders.

resultsAfter multivariable adjustment, vaccination against influenza was inversely associated with lymphoma (OR = 0.82; 95% CI, 0.66-1.02), which was stronger for last vaccination 1+ years before enrollment (OR = 0.71; 95% CI, 0.56-0.91) and for >5 influenza vaccinations (OR = 0.56; 95% CI, 0.46-0.68). Ever vaccination against hepatitis A (OR = 0.81; 95% CI, 0.66-1.00) but not hepatitis B (OR = 0.97; 95% CI, 0.81-1.18) was associated with lymphoma risk, although more recent vaccinations were inversely associated with lymphoma risk for both hepatitis A (<6 years before enrollment, OR = 0.56; 95% CI, 0.40-0.77) and hepatitis B (<9 years before enrollment, OR = 0.72; 95% CI, 0.55-0.93). Ever vaccination against yellow fever was inversely associated with risk (OR = 0.73; 95% CI, 0.55-0.96), and this did not vary by time since last vaccination. Although there was no overall statistical evidence for heterogeneity of vaccination history by lymphoma subtype, the only statistically significant inverse associations were observed for influenza and yellow fever vaccinations with diffuse large B-cell and follicular lymphoma.

conclusionsSelected vaccinations were inversely associated with lymphoma risk, with time since last vaccination relevant for some of these vaccines. IMPACT: Vaccinations against hepatitis A, hepatitis B, yellow fever, and influenza are unlikely to increase lymphoma risk.

Indexed as

Influenza, HumanInfluenza VaccinesLymphomaHumansLogistic ModelsVaccinationInfluenza Vaccines

Identifiers

PMID34782394
PMCPMC8825700
OpenAlexW3212800898

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.